Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
We propose a first interaction study between efavirenz (EFV) and R20mg/Kg taking into
consideration the absence of data about R induction at this dose. Due to an important
inter-patient variability of the CYP2B6 polymorphism, the EFV pharmacokinetic (Pk) will be
compared in same patients with and without TB treatment.
The main objective is to compare the Pk parameters of EFV in HIV-TB co-infected patients,
with and without TB treatment, using R at 10 and 20mg/Kg/day and EFV at 600 and 800mg/day.
Phase:
Phase 2
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)